Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-84807 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- PIK3R2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: EMQRILLNSE RLKSRIAEIH ESRTKLEQQL RAQASDN
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 0.4 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Efficient Delivery of Triptolide Plus a miR-30-5p Inhibitor Through the Use of Near Infrared Laser Responsive or CADY Modified MSNs for Efficacy in Rheumatoid Arthritis Therapeutics.
Zhang X, Zhang X, Wang X, Wang T, Bai B, Zhang N, Zhao Y, Yu Y, Wang B
Frontiers in bioengineering and biotechnology 2020;8:170
Frontiers in bioengineering and biotechnology 2020;8:170
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of PI3K p85 beta by a PI3K p85 beta polyclonal antibody (Product # PA5-84807). Analysis in human cell line RT-4 and human cell line U-251 MG.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of PI3K p85 beta in U-2 OS cells using a PI3K p85 beta polyclonal antibody (Product # PA5-84807). The analysis shows localization to the Golgi apparatus.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- FIGURE 1 miR-30-5p is overexpressed in RA clinical tissues and regulates the expression of PIK3R2 in the studied cell lines. (A) Relative mRNA expression of miR-30-5p in samples from 40 patients (28 males and 12 females) undergoing surgery was tested by qPCR. (B) Relative mRNA expression of PIK3R2 in HFLS cells transfected with miR-30-5p or miR-30-5p inhibitor, as determined by qPCR. (C) Protein expression of PIK3R2 in HFLS cells transfected with miR-30-5p or miR-30-5p inhibitor, as determined by Western blotting. Experiments in (B,C) were repeated three independent times ( * p < 0.05, ** p < 0.01, and *** p < 0.001).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- FIGURE 6 miR-30-5p inhibitor-loaded MSNs@CADY inhibited the proliferation and promoted the apoptosis of RASF cells by targeting PIK3R2. (A) The encapsulation efficiency of MSNs@CADY@miR-30-5p and MSNs@CADY@miR-30-5p inhibitor for miR-30-5p and miR-30-5p inhibitor was determined using semipermeable dialysis bags in PBS (pH 7.4) at 37degC. RASFs were treated with 100 mug/mL MSNs, MSNs@CADY, MSNs@CADY@miR-30-5p and MSNs@CADY@miR-30-5p inhibitor for 24 h. (B) Relative mRNA expression of miR-30-5p, PIK3R2, PI3K, and AKT as determined by qPCR. (C) Relative protein expression of PIK3R2, PI3K, p-PI3K, AKT, and p-AKT as determined by Western blot. (D) The cell number was determined after treatment with different nanodrug carriers for 0, 24, 48, and 72 h. The graph represents the cell growth curve for each group. (E) The RASF apoptosis level in each group was measured by Annexin V/PI staining. Experiments were repeated three independent times ( * p < 0.05, ** p < 0.01, and *** p < 0.001).
